Clinical course of 2 index patients subjected to precision-medicine–based treatment management. (A) Clinical course of the first patient highlighting the collection of samples for molecular diagnostics, blast levels, and administration of cancer drugs. The timeline provides a monthly view of the clinical events during the disease course and a yearly view of follow-up observations after allo-HSCT. (B) Depiction of the clonal evolution of the tumor of the first patient during transformation from diagnosis (blast level, 45%), through partial remission (blast level, 5%), to relapse (blast level, 85%). Analyses highlighted the major loss of the subclone, with mutations in ABL1 and RUNX1 at the second sampling. (C) Clinical course of the second patient, highlighting collection of samples for molecular diagnostics, blast levels, and administration of cancer drugs. The timeline provides a monthly view of clinical events during the disease course. (D) Depiction of the clonal evolution of the tumor of the second patient during transformation from diagnosis (blast level, 30%), through partial remission (blast level, 5%), to relapse (blast level, 20%). Analyses highlighted the acquisition of a subclone with mutations in ABL1, MSH6, and SETD1B genes at the second sampling.